These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 21262850)
21. Tapentadol - A representative of a new class of MOR-NRI analgesics. Zajączkowska R; Przewłocka B; Kocot-Kępska M; Mika J; Leppert W; Wordliczek J Pharmacol Rep; 2018 Aug; 70(4):812-820. PubMed ID: 29921501 [TBL] [Abstract][Full Text] [Related]
22. Tapentadol: an initial analysis. Prommer EE J Opioid Manag; 2010; 6(3):223-6. PubMed ID: 20642251 [TBL] [Abstract][Full Text] [Related]
23. Effect of Tapentadol on Splenic Cytokine Production in Mice. Franchi S; Amodeo G; Gandolla M; Moschetti G; Panerai AE; Sacerdote P Anesth Analg; 2017 Mar; 124(3):986-995. PubMed ID: 27997452 [TBL] [Abstract][Full Text] [Related]
25. Opioid and noradrenergic contributions of tapentadol to the inhibition of locus coeruleus neurons in the streptozotocin rat model of polyneuropathic pain. Torres-Sanchez S; Borges GDS; Mico JA; Berrocoso E Neuropharmacology; 2018 Jun; 135():202-210. PubMed ID: 29551688 [TBL] [Abstract][Full Text] [Related]
26. Unique pharmacology of tapentadol for treating acute and chronic pain. Knezevic NN; Tverdohleb T; Knezevic I; Candido KD Expert Opin Drug Metab Toxicol; 2015; 11(9):1475-92. PubMed ID: 26215077 [TBL] [Abstract][Full Text] [Related]
27. Effects of tapentadol on mechanical hypersensitivity in rats with ligatures of the infraorbital nerve versus the sciatic nerve. Michot B; Bourgoin S; Kayser V; Hamon M Eur J Pain; 2013 Jul; 17(6):867-80. PubMed ID: 23229959 [TBL] [Abstract][Full Text] [Related]
28. Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysis. Tzschentke TM; Folgering JH; Flik G; De Vry J Neurosci Lett; 2012 Jan; 507(2):151-5. PubMed ID: 22197547 [TBL] [Abstract][Full Text] [Related]
29. Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain. Meske DS; Xie JY; Oyarzo J; Badghisi H; Ossipov MH; Porreca F Neurosci Lett; 2014 Mar; 562():91-6. PubMed ID: 23969300 [TBL] [Abstract][Full Text] [Related]
30. Participation of ATP-sensitive K+ channels and μ-opioid receptors in the antinociceptive synergism of the paracetamol-tapentadol co-administration in the formalin-induced pain assay in mice. Zapata-Morales JR; Alonso-Castro ÁJ; Pérez-Gutiérrez S; Rojas-Bedolla EI; Sánchez-Enriquez S; Rivas-Carrillo JD; Serafín-Higuera NA; Isiordia-Espinoza MA Drug Dev Res; 2018 Dec; 79(8):400-405. PubMed ID: 30362140 [TBL] [Abstract][Full Text] [Related]
31. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Niesters M; Proto PL; Aarts L; Sarton EY; Drewes AM; Dahan A Br J Anaesth; 2014 Jul; 113(1):148-56. PubMed ID: 24713310 [TBL] [Abstract][Full Text] [Related]
32. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor. Hartrick CT; Rozek RJ CNS Drugs; 2011 May; 25(5):359-70. PubMed ID: 21476608 [TBL] [Abstract][Full Text] [Related]
33. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Tzschentke TM; Jahnel U; Kogel B; Christoph T; Englberger W; De Vry J; Schiene K; Okamoto A; Upmalis D; Weber H; Lange C; Stegmann JU; Kleinert R Drugs Today (Barc); 2009 Jul; 45(7):483-96. PubMed ID: 19834626 [TBL] [Abstract][Full Text] [Related]
35. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study. Kleinert R; Lange C; Steup A; Black P; Goldberg J; Desjardins P Anesth Analg; 2008 Dec; 107(6):2048-55. PubMed ID: 19020157 [TBL] [Abstract][Full Text] [Related]
36. Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain. Christoph T; De Vry J; Schiene K; Tallarida RJ; Tzschentke TM Eur J Pharmacol; 2011 Sep; 666(1-3):72-9. PubMed ID: 21640095 [TBL] [Abstract][Full Text] [Related]
37. Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine. Kaski SW; White AN; Gross JD; Trexler KR; Wix K; Harland AA; Prisinzano TE; Aubé J; Kinsey SG; Kenakin T; Siderovski DP; Setola V J Pharmacol Exp Ther; 2019 Nov; 371(2):487-499. PubMed ID: 31492823 [TBL] [Abstract][Full Text] [Related]
38. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Kögel B; Christoph T; Strassburger W; Friderichs E Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189 [TBL] [Abstract][Full Text] [Related]
39. Characterisation of tramadol, morphine and tapentadol in an acute pain model in Beagle dogs. Kögel B; Terlinden R; Schneider J Vet Anaesth Analg; 2014 May; 41(3):297-304. PubMed ID: 24576316 [TBL] [Abstract][Full Text] [Related]
40. Tapentadol for pain: a treatment evaluation. Hartrick CT; Rodríguez Hernandez JR Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]